Roche said the late-stage study of its arthritis drug indicated that ocrelizumab could help ease symptoms of a type of rheumatoid arthritis.

Roche said its phase III trial found that ocrelizumab was responsive as a treatment for seropositive rheumatoid arthritis patients with a previous inadequate response to methotrexate (MTX).

When in combination with MTX, ocrelizumab alleviated symptoms of the disease at week 24 and 48 of the trial more than patients who were just being treated with MTX.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData